The purpose of the study is to determine whether nerandomilast can more effectively delay death or disease worsening compared with the placebo.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year. During this time, they will attend regular clinic visits where doctors will check skin thickness, lung function (including a test called FVC that measures how much air can be forced out of the lungs), physical ability, and overall health. The study will track any serious health events, changes in symptoms, and overall survival throughout the treatment period.

The purpose of the study is to assess the safety and tolerability of the drug. In the first part, participants receive several doses that increase in amount over time; in the second part, all participants continue to receive the drug in an open‑label phase where both researchers and participants know the treatment. Throughout the trial, researchers monitor for side effects (AEs) and perform routine checks such as a heart test (ECG), laboratory analysis of blood and the fluid around the brain and spine (CSF), vital signs, weight and mental health screening. Blood and fluid samples are also taken to understand the drug’s pharmacokinetics, meaning how it is absorbed, distributed, and cleared from the body.

Participants attend regular clinic visits over several months, during which they receive the study medication, undergo the safety checks described above, and provide samples for analysis. The study does not provide any guarantee of benefit, and its primary aim is to gather information on how the drug is tolerated in people with this condition.

The study is designed to continue treatment for patients who have already participated in previous research with rocatinlimab. Participants will receive either rocatinlimab or placebo through injections under the skin. This is a long-term study that will monitor how well patients maintain improvement in their skin condition and any side effects that may occur during treatment.

The research will track various aspects of the skin condition, including changes in skin appearance, itching severity, and overall symptoms. The study will particularly focus on monitoring the safety of the treatment by recording any side effects and checking laboratory test results and vital signs throughout the treatment period.

Participants will first receive a single low dose of the medication, followed by a period of observation. After this initial phase, they may receive multiple increasing doses over several weeks, with regular clinic visits to check how the drug is processed in the body and to record any changes in seizure frequency. Samples of the fluid around the brain and spinal cord (CSF) and blood are taken to understand how the drug moves through the body, and seizure counts are recorded to see if there is any improvement. Throughout the study, doctors closely watch for any adverse events and adjust the plan as needed.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

The study is a follow-up, or extension, of earlier research and is designed to continue for a long period. During the study, participants will take the study tablets and return for regular checkups so the study team can watch for any health problems and see how the treatment is being tolerated over time. The study compares the two remibrutinib doses with placebo in a blinded way, which means the treatment given is not revealed to the participants or the study team during the study.

Adults and adolescents in the study are assigned by chance to receive either GB-0895 or placebo, and neither the participants nor the study team knows which one is given during the study. Treatment is given over about 52 weeks, with regular study visits during that time. The study looks at how asthma changes over the year, including flare-ups, breathing, asthma symptoms, and daily life with asthma.

Some medical terms used in the study include exacerbations, which means asthma flare-ups that are bad enough to need steroid medicine or a hospital or emergency room visit, and forced expiratory volume in 1 second (FEV1), which is the amount of air that can be blown out in one second. The study also uses systemic corticosteroids, which are steroid medicines that work throughout the body.

The study is a long-term extension, which means it follows people over a longer period after earlier treatment. During the trial, the medicine is taken by mouth and participants are watched over time for side effects and other health changes. Regular checkups and laboratory tests are used to follow general health, joint symptoms, and skin symptoms while treatment continues.

In the study, people are randomly assigned to receive either the new treatment combination or the standard treatment combination. The medicines are given as intravenous infusion, which means they are delivered slowly through a vein. Treatment is given in cycles over time, with regular visits for infusions and checks by the study team. The study will look at how long people live and will also follow symptoms and side effects, including breathing problems, chest pain, cough, and treatment-related reactions such as CRS and ICANS. CRS, or cytokine release syndrome, is a strong immune reaction that can cause fever and other symptoms. ICANS, or immune effector cell-associated neurotoxicity syndrome, is a brain and nerve problem that can affect thinking, speech, or alertness.

The goal of the study is to see how pegtibatinase affects levels of total homocysteine (tHcy) and methionine (Met) in the blood. High levels of these substances are common in people with this disease. During the study, blood samples will be taken to monitor these levels and to ensure that the treatment is being tolerated well by the body.

During the initial part of the study, participants will receive either the medication or the placebo for a period of 24 weeks. The study will monitor how the treatment affects lung function, specifically looking at the forced vital capacity, which is the total amount of air a person can exhale after taking a deep breath. Following this period, there is an option to continue in an extended phase of the study for an additional 24 weeks.

Participants in the study will receive either the test medication NNC0662-0419, a comparator drug named Ozempic, or a placebo. The study will monitor changes in HbA1c, which is a blood test that shows the average blood sugar levels over the past few months. Additionally, changes in body weight will be observed during the course of the research.

Participants may receive different combinations of medications. One group will receive blinatumomab alternating with low-intensity chemotherapy, which is a type of treatment that uses drugs to kill cancer cells. The other group will receive the standard of care, which includes medications such as rituximab, cytarabine, dexamethasone, vincristine sulfate, cyclophosphamide, methotrexate sodium, mercaptopurine, prednisone, idarubicin, asparaginase, and doxorubicin. Other substances mentioned in the study include pegaspargase, crisantaspase, and prednisolone.

The study will monitor how long patients live and how long they stay without the cancer returning. Researchers will also look at the minimal residual disease, which refers to the small number of cancer cells that remain in the body after treatment. Additionally, the study will track how the treatments affect the patients’ quality of life, including levels of pain, tiredness, and physical function.

The purpose of the study is to determine if BI 764198 is more effective than a placebo at reducing the amount of protein leaked into the urine. During the study, participants will take either the active medication or a placebo in the form of an oral film-coated tablet. The treatment period lasts for 104 weeks, and the process is double-blind, meaning neither the participants nor the researchers know which treatment is being administered during the trial.

Participants in the study will receive either ADX-038 or a placebo through a subcutaneous injection, which is a method of delivering medication into the fatty tissue just beneath the skin. The study will monitor changes in the size of the affected areas and the health of the photoreceptors, which are the specialized cells in the eye that respond to light. This process involves using advanced imaging techniques such as optical coherence tomography, a non-invasive way to take cross-section pictures of the retina, and fundus autofluorescence, a specialized eye imaging test that helps visualize the health of the retinal layers.

Participants in the study will be assigned to receive either L606 or a placebo. This research involves a randomized and double-blind process, meaning that neither the participants nor the researchers know which specific treatment is being administered until the study is finished. The study will monitor how the medication affects the ability to walk and other health factors over a period of time.

The purpose of the study is to compare the effectiveness of different medication combinations in preventing the cancer from getting worse. One group will receive a combination of sotorasib, panitumumab, and FOLFIRI. FOLFIRI is a treatment plan that includes fluorouracil, irinotecan hydrochloride trihydrate, and calcium folinate, all of which are administered through intravenous use, meaning they are delivered directly into a vein. Another group will receive FOLFIRI either alone or combined with bevacizumab.

Participants will be assigned to one of these treatment groups to see which approach is better at managing the disease. The study will follow the progress of the cancer over time to observe how long the treatments keep the disease from spreading further or increasing in size.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

The main goal of the study is to see how well each medicine cleans the bowel by measuring the cleanliness using a scoring system called the Boston Bowel Preparation Scale. The study will also look at how well children can follow the instructions for taking the medicine, how easy it is to drink, how it tastes, and whether children experience any unwanted effects from the medicine. Participants will be randomly assigned to receive either PLENVU or sodium picosulfate, meaning it will be decided by chance which medicine they get, similar to flipping a coin. The doctor performing the colonoscopy will not know which medicine the child received, which helps make the comparison fair.

During the study, children will take the bowel cleansing medicine at home before coming to the hospital or clinic for their colonoscopy. They or their parents will keep track of how much of the medicine they were able to drink and answer questions about how they felt while taking it. The colonoscopy will be performed as planned, and the doctor will score how clean the bowel is. After the colonoscopy, there will be a follow-up period to check on the child’s safety and well-being. The study is expected to start enrolling participants in early 2026 and finish in early 2027.

This study is an extension study, which means some participants may join after completing a previous study with finerenone, while other newly enrolled infants under 6 months of age can join directly if they meet certain health requirements. During the study, participants will receive finerenone along with their regular heart failure medications. The study will monitor various safety measures including blood potassium levels, blood pressure, and kidney function, as well as checking for any unwanted effects of the treatment. The study will also measure levels of a substance called NT-proBNP in the blood, which is a marker of heart function, and will use imaging with echocardiography to see how well the heart is working.

The study will last for approximately 270 days for each participant. Throughout this time, regular visits will be scheduled to check the safety and effects of the treatment. Blood samples will be collected to measure how much finerenone is in the body. For participants using the granules for oral suspension, there will be questions about the taste and texture of this form of the medicine. The study will track any side effects or health changes that occur during treatment.

The purpose of the study is to compare how well DS-8201a works compared to standard chemotherapy in preventing the cancer from coming back. The study will look at how long participants remain free of disease after treatment. Participants will be randomly assigned to receive either DS-8201a or one of the standard chemotherapy combinations. All medications will be given through a vein as an infusion. The treatment period can last up to 51 cycles for DS-8201a or between 4 to 18 cycles for the standard chemotherapy options, depending on which treatment is assigned. A cycle is a repeating period of time during which the medication is given.

During the study, participants will have regular check-ups that include imaging scans to look for any signs of cancer returning, blood tests to check organ function and blood cell counts, heart function tests using ultrasound or similar scans, and eye examinations. The study will also measure how participants feel and their quality of life using questionnaires. The doctors will monitor for any side effects or unwanted reactions to the medications throughout the study. The study will also collect blood samples to measure the levels of the study medication in the body and to check if the body develops any immune response to the treatment.

The trial has two parts. The first part is a safety run-in phase where a small group of patients will receive BNT113 combined with pembrolizumab to check if the combination is safe and well-tolerated. The second part is a randomized phase where patients will be assigned by chance to receive either the combination of BNT113 and pembrolizumab or pembrolizumab alone. During the trial, doctors will monitor how the cancer responds to treatment and will check for any side effects. Patients will need to have regular visits, blood tests, and scans to see how well the treatment is working.

The trial will measure several outcomes including how long patients live, how long it takes before the cancer grows or spreads, and whether the cancer shrinks or disappears. Doctors will also carefully track any side effects that occur during treatment. The trial will use imaging scans to measure changes in tumor size and will follow patients for up to several years to gather information about the long-term effects of these treatments.

Participants in this study will have been diagnosed with Parkinson’s Disease and will already be taking medication for their condition for at least three months. The study will look at whether prasinezumab can delay the time it takes for movement problems to get worse. Prasinezumab will be given through an intravenous infusion, which means it will be delivered directly into a vein. The study will measure various aspects of how participants move and function, including detailed assessments of motor function, which refers to how well a person can control their body movements.

During the study, doctors will carefully monitor participants for any side effects or unwanted reactions to the treatment. This includes checking for infusion-related reactions, which are responses that can happen when medication is given through a vein. Regular health checks will be performed, including measurements of vital signs such as blood pressure and heart rate, blood tests, and assessments of overall wellbeing. The study will also track changes in the amount of Parkinson’s Disease medication that participants need to take over time, as well as how participants feel about changes in their condition.

The purpose of this study is to find out how many injections people need after receiving the gene therapy compared to those who continue getting regular injections of ranibizumab, and to see how well the gene therapy works in preserving vision over time in a setting that is similar to everyday medical practice. The study will also look at the safety of the gene therapy and measure any side effects that may occur in the treated eye or the other eye. Additionally, the study will check for changes in areas of damage in the central part of the retina.

People taking part in the study will be randomly assigned to receive either the gene therapy or ranibizumab. Those who receive the gene therapy will have it injected under the retina during a surgical procedure, while those in the comparison group will receive ranibizumab injections into the eye as needed based on how their condition responds. During the first year, people will be monitored closely and receive additional injections if needed according to specific guidelines. After the first year, the treatment schedule will follow a more flexible approach that reflects how treatment is typically managed in regular clinics. The study will last for several years to see how well vision is maintained over the long term.

The purpose of this study is to compare how well MK-2870 combined with pembrolizumab works compared to pembrolizumab alone in preventing the cancer from coming back after surgery. Before being assigned to one of these treatment groups, participants will first receive pembrolizumab along with platinum-based chemotherapy before surgery, which is called neoadjuvant treatment. After surgery, if cancer cells are still found in the removed tissue, meaning a complete response was not achieved, participants will then be randomly assigned to receive either MK-2870 plus pembrolizumab or pembrolizumab alone as adjuvant treatment, which means treatment given after surgery to reduce the risk of cancer returning.

During the study, participants will have regular check-ups that include imaging scans such as computed tomography or magnetic resonance imaging to monitor for any signs of cancer returning. The study will measure how long participants remain free of disease, how long they survive overall, and whether the cancer spreads to distant parts of the body. Researchers will also assess quality of life and monitor for any side effects throughout the treatment period. The treatment period can last up to several months, and participants will continue to be followed for a number of years to track long-term outcomes.

The study has a double-blind design, which means that neither the participants nor the doctors will know who is receiving the actual medication and who is receiving placebo. Before starting treatment, participants will complete a baseline period where they record their headaches and migraines in an electronic diary. During this time, they must have at least 4 but fewer than 15 migraine days and fewer than 15 total headache days in a 28-day period. The main treatment phase lasts for 12 weeks, during which participants will receive injections of either erenumab or placebo. The maximum treatment period can extend up to 83 weeks, with the highest dose being 140 milligrams per injection.

Throughout the study, participants will continue to record their headaches and migraines in the electronic diary to track changes in the number of migraine days per month. The study will also measure changes in the number of total headache days, the severity of migraine attacks, and how much migraine affects daily activities and school performance. The main focus is on comparing the change in monthly migraine days between those receiving erenumab and those receiving placebo during weeks 9 through 12 of the treatment phase. Participants must have had a history of migraine with or without aura for at least 12 months before joining the study, and the diagnosis must follow established international headache classification criteria.

The purpose of this study is to assess the long-term safety and tolerability of Navenibart in people with Hereditary Angioedema. The study will also look at how well the medication works in preventing swelling attacks over an extended period of time. Participants in this study will be people who previously took part in another study called STAR-0215-301 and either completed that study or received at least two doses of the medication and were followed for at least two months after the second dose.

During the study, participants will receive regular doses of the medication, with a maximum daily dose of 600 milligrams and a total maximum dose of 9600 milligrams over a treatment period of up to 48 weeks. The study will track any side effects or health problems that occur during treatment. Researchers will also count how many swelling attacks participants experience, including how many are moderate or severe, and how many require emergency treatment. The study will measure whether participants have fewer attacks compared to before treatment, including whether they achieve reductions of 50 percent, 70 percent, or 90 percent in their attack rate, or whether they have no attacks at all. Quality of life will be measured using a questionnaire specifically designed for people with swelling conditions.

The purpose of this study is to find out if adding Revumenib to intensive chemotherapy helps people with this type of leukemia live longer without their disease getting worse compared to chemotherapy alone, and to see if this combination helps more people achieve complete remission with no detectable signs of cancer cells remaining in their bone marrow. During the study, participants will receive their assigned treatment and will be monitored regularly to check how well the treatment is working and to watch for any side effects. The study will track various outcomes including how long participants live, how long they remain in remission, and how many participants achieve complete remission with no measurable remaining disease.

The study will also carefully monitor the safety of the treatment by recording any unwanted effects that occur, checking blood test results regularly, and performing heart function tests and other examinations. Doctors will measure treatment success by looking at whether the cancer goes away completely, whether cancer cells can still be detected in the bone marrow or blood using special tests, and how long participants remain free of cancer. The study is expected to continue for several years to gather enough information about the long-term effects of this treatment combination.

The purpose of this study is to find out whether zilebesiran can reduce the risk of serious heart-related problems compared to placebo when added to standard blood pressure treatment. The study will look at whether the medication can prevent major events such as death from heart problems, heart attacks, strokes, or episodes of heart failure that require urgent medical attention or hospital admission. Heart failure is a condition where the heart cannot pump blood effectively enough to meet the body’s needs.

During the study, participants will receive injections of either zilebesiran or placebo while continuing their regular blood pressure medications. The study will measure blood pressure readings at regular visits and will track any heart-related health events that occur over time. Participants will be followed for several years to determine whether the treatment helps prevent serious cardiovascular problems. The study will also monitor how well the medication lowers blood pressure and whether it affects the risk of different types of heart and blood vessel complications.

During the study, people will receive different doses of RO7268489 or placebo in addition to their regular ocrelizumab treatment. The study will look at how well the medication works by checking if disability gets worse over time. This will be measured by looking at walking ability, hand function, and thinking skills. The study will also check how safe the medication is by watching for any unwanted effects and by doing regular health checks including blood tests and heart monitoring.

People taking part will need to wear a device that measures how they walk. The study will also measure the levels of certain substances in the blood to understand how the medication works in the body. The study will last for several years and will compare the results between people taking RO7268489 and those taking placebo to determine if the medication is helpful in slowing down the progression of multiple sclerosis.

The purpose of the study is to compare how well the different treatment combinations work against the cancer. Participants will be randomly assigned to receive either the new combination with JNJ-61186372 or the standard treatment. During the study, doctors will monitor how the cancer responds to treatment and track how long participants live. They will also check for any side effects or problems that might occur with the treatments.

Throughout the study, participants will have regular check-ups where doctors will measure the size of the cancer using imaging scans and assess overall health. The study will also look at quality of life and symptoms by asking participants to complete questionnaires about how they are feeling and how the treatment affects their daily activities. Blood samples will be collected to measure medication levels in the body and to check for any immune responses to the treatment. The study will continue for several years to fully understand the long-term effects of these treatment combinations.

People taking part in the study will be randomly assigned to receive either one injection of the experimental treatment or regular injections of the approved medication. Before starting the main part of the study, participants will receive one injection of the approved medication to make sure their condition responds to this type of treatment. During the study, doctors will measure vision using an eye chart and will take images of the eye to see how the condition is changing. The main measurement will be the change in vision after one year of treatment. Doctors will also track how many additional injections are needed and whether the experimental treatment can reduce the need for repeated injections compared to the standard treatment.

The study will last several years and will continue to follow participants to see how long the effects of the treatments last. Throughout the study, participants will have regular visits where their vision will be tested and their eyes will be examined. The study aims to determine whether the single injection of gene therapy can provide lasting benefits and reduce the treatment burden for people with this eye condition.

The purpose of the study is to learn how empagliflozin works in the bodies of children and teenagers with chronic kidney disease, to see if it is safe for them, and to find out if it helps their kidney disease. The study will measure how much of the medicine gets into the blood, check for any unwanted effects, and see if the medicine helps improve kidney function. The study will look at changes in protein levels in the urine, which is one way to measure how well the kidneys are working, and changes in how well the kidneys filter waste from the blood.

The study has two parts. In the first part, participants will be randomly assigned to receive either empagliflozin or placebo for 24 weeks, and neither the participants nor the doctors will know which treatment they are receiving. After this period, there will be an open-label extension where all participants will know they are receiving empagliflozin. The total treatment period can last up to 72 weeks. During the study, participants will continue taking their regular medicines for kidney disease, which may include medicines that help protect the kidneys. Regular check-ups will be done to monitor the participants’ health and kidney function throughout the study.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The study will compare these medications to placebo to see if they can help reduce agitation symptoms in people with Alzheimer’s Disease. During the study, participants will be randomly assigned to receive either the study medications or placebo. Neither the participants nor their doctors will know which treatment they are receiving.

The main way of measuring if the treatment works will be through a special rating scale that measures agitation behaviors. Throughout the study, participants will need to have a caregiver who spends at least 10 hours per week with them to help monitor their condition and assist with taking the medication correctly.

The study will involve people with mild to moderate Alzheimer’s Disease, who will receive either the study medications or placebo for 24 weeks. The medications are being tested to see if they can help improve cognitive function (thinking abilities) and daily functioning in people with Alzheimer’s Disease.

During the study, participants will take the medication daily and attend regular check-ups where their mental abilities and overall condition will be assessed. The study will track any changes in participants’ ability to think, perform daily activities, and their overall health status. Healthcare providers will monitor participants’ safety throughout the study period.

The medications being tested contain active substances called trospium chloride and xanomeline tartrate. They come in the form of capsules that are taken by mouth. The study will involve patients who have previously participated in related research studies of these medications.

During the study, researchers will monitor various aspects of participants’ health, including any side effects, changes in body weight, blood pressure, heart rate, and mental function. They will also check for any unusual movements, restlessness, and other health-related factors to ensure the medications’ safety over extended use.

The main purpose of this research is to determine if izalontamab brengitecan works better than standard chemotherapy treatments in patients who cannot receive certain types of immunotherapy treatments (anti-PD1/PD-L1). The study will measure how long patients live without their cancer getting worse and their overall survival time. During treatment, some patients may also receive pegfilgrastim, a supportive care medicine that helps the body make white blood cells.

The medications will be given in different ways – some through an intravenous infusion directly into a vein, while others, like capecitabine, are taken by mouth as tablets. The study will continue for several years to gather information about how well the treatments work and how safe they are for patients.

The study compares Navenibart against placebo to determine how effective it is in reducing the frequency of HAE attacks. During the study, participants will receive either Navenibart or placebo as a subcutaneous (under the skin) injection. The treatment period lasts for 6 months, during which participants will be monitored for any HAE attacks and their severity.

Throughout the study, researchers will track how many HAE attacks occur and how severe they are. They will also monitor the overall well-being of participants and any changes in their quality of life. The medication will be tested in both adults and adolescents with HAE to evaluate its safety and effectiveness in preventing attacks.

The study involves patients whose lung cancer has already been treated with platinum-based chemotherapy combined with immunotherapy but has since returned. Both medications in this study will be given through intravenous infusion (delivered directly into a vein). GSK5764227 will be given at doses up to 8 milligrams per kilogram of body weight, while topotecan will be given at doses up to 1.5 milligrams per square meter of body surface area.

This is an open-label study, which means both the doctors and patients will know which treatment is being given. The treatment period may last up to 24 months, during which time doctors will monitor how well the cancer responds to the treatment and track the overall survival of patients. Throughout the study, patients will have regular check-ups to monitor their health and assess how well the treatment is working.